Worst Pills, Best Pills

An expert, independent second opinion on more than 1,800 prescription drugs, over-the-counter medications, and supplements

isocarboxazid (MARPLAN)


E-ALERTS

Search results below include E-Alerts where your selected drug is a secondary subject of discussion.


DRUG AND DIETARY SUPPLEMENT PROFILES

A comprehensive review of the safety and effectiveness of this drug. If the drug is not a Do Not Use product, information on adverse effects, drug interactions and how to use the medication are included.
Search results below include Drug and Dietary Supplement Profiles where your selected drug is a secondary subject of discussion.

dexmethylphenidate (FOCALIN, FOCALIN XR)
  • We list this drug as a Do Not Use drug because it has no advantage over similar drugs with longer safety records.

WORST PILLS, BEST PILLS NEWSLETTER ARTICLES

Search results below include Worst Pills, Best Pills Newsletter Articles where your selected drug is a secondary subject of discussion.

Removing Tianeptine Products From the U.S. Market: Stronger FDA Actions Needed
August 2024
Tianeptine is an addictive synthetic chemical substance with opioid-like effects that is associated with serious health risks and even death. The Food and Drug Administration (FDA) classifies tianeptine as an unsafe food additive and has not approved it for any medical use. Stronger FDA actions are needed to remove tianeptine from the U.S. market.
Do Not Take Central Nervous System Stimulants for Weight Loss!
August 2019
Learn why Public Citizen’s Health Research Group advises against using any central nervous system stimulant drugs for weight loss.
Do Not Use: Duloxetine (CYMBALTA)
June 2012
We review the dangers of the extremely popular drug duloxetine (CYMBALTA) and discuss why you should not use it to treat depression, anxiety or pain.
Do Not Use Until October 2005 Escitalopram (LEXAPRO) – The Sixth Selective Serotonin Reuptake Inhibitor (SSRI) Antidepressant
January 2003
Escitalopram (LEXAPRO) was approved by the Food and Drug Administration (FDA) in August 2002 and brings to six the number of selective serotonin reuptake inhibitor (SSRI) antidepressants now on the market in the U.S. The primary purpose for developing escitalopram appears to be nothing more than a strategy to protect sales as citalopram nears the end of its patent protection. In the long run, escitalopram will cause economic harm to individuals and the healthcare system.
Do Not Use! Dexmethylphenidate (FOCALIN) - a Methylphenidate (RITALIN) Copy
August 2002
Dexmethylphenidate (FOCALIN), approved by the Food and Drug Administration (FDA) in November 2001 for attention-deficit/hyperactivity disorder (ADHD), joins a growing list of Do Not Use drugs, so called because they primarily result in economic harm to both individuals and the health care system. These drugs exist solely to extend a manufacturer’s brand name monopoly position in a lucrative market but offer nothing better than the drugs they replace.